"This is the first study evaluating the activity of a selective CRP inhibitor, and we are extremely pleased with the activity and safety of ISIS-CRPRx. Based on the substantial reductions in CRP that we observed in the cohort of subjects who had elevated levels of CRP, we expect to see CRP reductions at much lower doses in our Phase 2 studies. In these studies, we will evaluate ISIS-CRPRx in patients with elevated CRP levels in a variety of diseases, including multiple myeloma and rheumatoid arthritis. The results from these initial studies will help us inform the rest of our Phase 2 development program for CRP, in which we will expand into other disease areas," commented Richard Geary, Ph.D., Senior Vice President of Development at Isis. "Chronically elevated levels of CRP have been linked to cardiovascular disease and associated with a worsening of overall outcome in conditions such as end-stage renal disease, suggesting that lowering CRP in these patients could be beneficial."
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerat
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved